Lavie Bio, a subsidiary of Evogene, has announced the expansion of its microbiome-based product Yalos™ to include durum and barley, significantly broadening its potential market reach. The product, which enhances production by improving soil nutrients, reducing environmental stress, and increasing yields, had already shown success in field trials for spring wheat.
The 2023 trials for durum and barley in the US exceeded expectations, with an average production improvement of 8.3% for durum and 6.6% for barley. Yalos™ combines two natural microbes discovered by Lavie Bio’s advanced BDD platform, powered by Evogene’s MicroBoost AI tech-engine.
Chad Rubbelke, owner of Rubbelke Farms, praised the product’s performance, stating that “Yalos™ has been impressive on our farm. In my mind Yalos™ is a strong competitor in the biological market and pays for itself yearly.”
Lavie Bio’s CEO, Amit Noam, expressed satisfaction with the results of the field trials and stated that the company remains dedicated to commercial growth by expanding to additional crops across the United States, Canada, and beyond. The expansion increases the product’s addressable market in the US and Canada by around 40%, from 25 million acres to 35 million acres.
As Lavie Bio continues to lead the agricultural innovation frontier, championing sustainable practices and enhancing crop yields, it remains committed to commercial growth through expanding its product range and geographic reach.